

## Statement regarding use of non-GAAP financial measures

In this press release, the company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached schedules and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights.
- Goodwill and long-lived asset impairment charges – impairment charges on long-lived assets and goodwill.
- Equity compensation – non-cash equity-based compensation provided to Myriad employees and directors.
- Transformation initiatives – transitory costs such as consulting and professional fees related to transformation initiatives.
- Gain on sale – gain, net of transaction costs, recognized on our divestitures of the Myriad myPath, LLC laboratory, Myriad RBM, Inc. and the Myriad Autoimmune business.
- Divestiture-related costs – non-recurring costs associated with our divestitures of the Myriad myPath, LLC laboratory, Myriad RBM, Inc. and the Myriad Autoimmune business.
- Legal accrual - we have accrued \$48.0 million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the company.
- Other adjustments – other one-time non-recurring expenses including expenses related to leadership transition, severance and retention agreements, legal expenses and changes in the fair value of contingent consideration related to acquisitions from prior years.

- Tax impact associated with non-GAAP adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and CARES Act legislation.

**Reconciliation of GAAP to Non-GAAP Financial Measures  
for the Three and Nine months ended September 30, 2021 and 2020**

(unaudited data in millions, except per share amount)

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Adjusted Gross Margin</b>				
GAAP Gross Profit <sup>(1)</sup>	\$ 119.5	\$ 101.0	\$ 378.0	\$ 271.4
Equity compensation	0.4	0.3	1.0	1.0
Other adjustments	0.1	—	1.3	—
Adjusted Gross Profit	\$ 120.0	\$ 101.3	\$ 380.3	\$ 272.4
Adjusted Gross Margin	72%	70%	72%	68%

(1) Consists of total revenues less cost of molecular diagnostic testing and cost of pharmaceutical and clinical services from the Condensed Consolidated Statements of Operations.

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Adjusted Operating Expenses</b>				
GAAP Operating Expenses <sup>(2)</sup>	\$ 199.4	\$ 140.6	\$ 525.4	\$ 513.0
Acquisition - amortization of intangible assets	(11.5)	(15.2)	(40.3)	(45.5)
Goodwill and long-lived asset impairment charges	—	—	(1.8)	(98.4)
Equity compensation	(9.6)	(8.1)	(26.9)	(16.8)
Transformation initiatives	(6.0)	(1.9)	(18.8)	(9.6)
Divestiture-related costs	(0.1)	—	(1.8)	—
Legal accrual	(48.0)	—	(48.0)	—
Other adjustments	(2.7)	(2.0)	(16.4)	(3.7)
Adjusted Operating Expenses	\$ 121.5	\$ 113.4	\$ 371.4	\$ 339.0

(2) Consists of research and development expense, change in the fair value of contingent consideration, selling, general, and administrative expense, and goodwill and long-lived asset impairment charges from the Condensed Consolidated Statements of Operations.

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Adjusted Operating Income (Loss)</b>				
GAAP Operating Loss	\$ (79.9)	\$ (39.6)	\$ (147.4)	\$ (241.6)
Acquisition - amortization of intangible assets	11.5	15.2	40.3	45.5
Goodwill and long-lived asset impairment charges	—	—	1.8	98.4
Equity compensation	10.0	8.4	27.9	17.8
Transformation initiatives	6.0	1.9	18.8	9.6
Divestiture-related costs	0.2	—	1.9	—
Legal accrual	48.0	—	48.0	—
Other adjustments	2.8	2.0	17.7	3.7
Adjusted Operating Income (Loss)	\$ (1.4)	\$ (12.1)	\$ 9.0	\$ (66.6)

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Adjusted Net Income (Loss)</b>				
GAAP Net Income (Loss) Attributable to Myriad Genetics, Inc. Stockholders	\$ 24.6	\$ (15.2)	\$ (19.6)	\$ (185.8)
Acquisition - amortization of intangible assets	11.5	15.2	40.3	45.5
Goodwill and long-lived asset impairment charges	—	—	1.8	98.4
Equity compensation	10.0	8.4	27.9	17.8
Transformation initiatives	6.0	1.9	18.8	9.5
Gain on sale	(120.4)	—	(151.6)	—
Divestiture-related costs	0.1	—	14.5	—
Legal accrual	48.0	—	48.0	—
Other adjustments	2.0	3.5	16.9	4.2
Tax impact of non-GAAP adjustments	16.5	(25.1)	6.0	(30.6)
Adjusted Net Income (Loss)	\$ (1.7)	\$ (11.3)	\$ 3.0	\$ (41.0)
Weighted average shares outstanding:				
Basic	78.8	74.7	77.3	74.6
Diluted	78.8	74.7	79.8	74.6
Adjusted Net Income (Loss) Per Share				
Basic	\$ (0.02)	\$ (0.15)	\$ 0.04	\$ (0.55)
Diluted	(0.02)	(0.15)	0.04	(0.55)

**Adjusted Free Cash Flow Reconciliation**  
**for the Three and Nine Months Ended September 30, 2021 and 2020**  
*(unaudited data in millions)*

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Cash flow from operations</b>	\$ (39.3)	\$ (59.3)	\$ 28.1	\$ (12.5)
Capital expenditures	(3.0)	(1.5)	(14.6)	(6.8)
Free cash flow	\$ (42.3)	\$ (60.8)	\$ 13.5	\$ (19.3)
Transformation initiatives	6.0	1.9	18.4	9.5
Other adjustments	2.0	2.2	5.2	4.7
Tax impact associated with non-GAAP adjustments	(1.9)	(1.0)	(5.3)	(3.8)
Adjusted Free cash flow	\$ (36.2)	\$ (57.7)	\$ 31.8	\$ (8.9)